CytomX Therapeutics Inc
$ 3.01
1.01%
12 Jun - close price
- Market Cap 655,286,000 USD
- Current Price $ 3.01
- High / Low $ 3.04 / 2.96
- Stock P/E N/A
- Book Value 1.47
- EPS -0.52
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.34 %
- 52 Week High 8.21
- 52 Week Low 1.72
About
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$12.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-16 | 2025-11-06 | 2025-08-07 | 2025-05-12 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-11 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.1 | -0.22 | -0.09 | -0.0012 | 0.27 | 0.23 | 0.07 | -0.08 | 0.17 | 0.01 | 0.04 | -0.02 |
| Estimated EPS | -0.0972 | -0.0937 | -0.05 | -0.06 | 0.1322 | -0.1059 | -0.17 | -0.14 | -0.08 | -0.03 | -0.19 | -0.2 |
| Surprise | -0.0028 | -0.1263 | -0.04 | 0.0588 | 0.1378 | 0.3359 | 0.24 | 0.06 | 0.25 | 0.04 | 0.23 | 0.18 |
| Surprise Percentage | -2.8807% | -134.7919% | -80% | 98% | 104.236% | 317.186% | 141.1765% | 42.8571% | 312.5% | 133.3333% | 121.0526% | 90% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTMX
2026-06-09 22:39:32
Following positive early-stage trial data for its lead asset Varseta-M in metastatic colorectal cancer, CytomX Therapeutics (CTMX) has received multiple price target revisions from analysts. Jefferies raised its price target to $16-$18, indicating a potential upside of up to 230%, while Guggenheim also increased its target to $15, citing the drug's strong performance compared to existing standards of care. All nine analysts covering CTMX currently rate the stock as 'Buy' or higher, with an average 12-month price target of $11.67.
2026-06-08 14:09:17
Schulhoff & Co. Inc. has acquired a new stake of 374,850 shares in CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the fourth quarter, valued at approximately $1.6 million. This investment highlights broader institutional interest, with hedge funds and other institutional investors collectively owning 67.77% of the company's stock. Analysts maintain a "Moderate Buy" rating for CTMX, with an average target price of $12.10, significantly above its last trading price of $3.00.
2026-06-04 20:10:42
CytomX Therapeutics (CTMX) has made significant progress with its Probody platform and expanded its collaboration with Regeneron, securing substantial funding. Their drug Varseta-M has shown strong efficacy and a manageable safety profile in advanced colorectal cancer, with pivotal trials and combination studies planned for the future. This information is based on the company's Jefferies Global Healthcare Conference 2026 Audio Transcript.
2026-06-04 12:08:44
CytomX Therapeutics (CTMX) is an oncology-focused biopharmaceutical company with a market cap of US$692.3m. The stock is considered 70.0% undervalued by analysts and its revenue is forecast to grow 37.37% per year, despite being currently unprofitable. Recent updates include positive Phase 1 data for Varsetatug Masetecan in colorectal cancer and various leadership appointments and financial estimate revisions.
2026-06-03 16:41:29
CytomX Therapeutics saw its shares rise following an expanded licensing agreement with Regeneron Pharmaceuticals. The deal builds on a collaboration initiated in 2021, focusing on the development of bispecific anticancer therapeutics using CytomX's Probody platform. Under the new terms, CytomX will receive an upfront payment and could be eligible for significant milestone payments and royalties.
2026-06-02 18:10:57
CytomX Therapeutics announced positive Phase I dose expansion data for Varseta-M in late-line colorectal cancer patients, showing strong anti-tumor activity with confirmed overall response rates of 32% and 20% at its highest dose levels. The company has made significant progress in managing treatment-related diarrhea, reducing the Grade 3 rate to 10% in dose optimization cohorts through dual prophylaxis and adjusted ideal body weight dosing. CytomX plans to advance Varseta-M into registrational studies in the first half of 2027, with anticipated expansion into earlier lines of CRC therapy and other EpCAM-positive solid tumors.
